A proprietary tomato extract – backed in EU health claim law to benefit blood circulation – has been shown to thin blood in healthy people – but less severely than aspirin and without typical side-effects.
The bioavailability of micronutrients in a proprietary curcuminoid formulation is seven times more potent than 95% pure curcuminoids, say researchers from the Indian manufacturer Olive Lifesciences.
Research has called into question the role of plant polyphenols in cardiovascular health, by finding that their supposed anti-platelet activities are only relevant at high, and physiologically unattainable, concentrations.
DSM Nutritional Products claims that a market hungry for proven functional food ingredients will ensure the success of its ‘platelet smoothing’ tomato extract Fruitflow.
Biotech start-up Provexis says it will commence two clinical trials in 2011 – one in the area of cardiovascular inflammation, the other in treatment of “hospital superbug” c.difficile.
Re-formatting and re-submitting rejected, article 13.1 health claim dossiers under article 13.5 will not miraculously turn red lights green as many are hoping, according to a leading European health claims expert.
More than six months after receiving a positive health claim opinion from the European Food Safety Authority (EFSA) linking its tomato extract to blood circulation benefits, UK biotech firm Provexis has been handed final claim wording by the European...
Danone, the French dairy giant, will resubmit withdrawn gut and immunity probiotic health claims to the European Food Safety Authority (EFSA), after receiving guidance from the European Union’s head science body.
UK-based Provexis Natural Products Limited has won a positive article 13.5 claim linking tomato concentrate consumption and blood platelet aggregation from the European Food Safety Authority (EFSA).
Spanish researchers have shown that virgin olive oil (VOO) extracts can benefit heart and circulation health by reducing platelet aggregation in a study conducted on rats.
Functional ingredient innovator Provexis has secured a new 12-month
deal with Unilever to investigate the use of its Fruitflow
technology in the multinational's spreads brands.
A deal between Provexis and Coca-Cola over the use of its
tomato-based Fruitflow technology could be on the cards, according
to The Times, which may see heart health functional drinks
propelled into the mainstream.
Provexis is seeking to raise new funds to bolster its working
capital, after depleting its coffers with the extended timeline for
developing an advanced form of its Fruitflow technology.
Provexis has extended discussions over the use of its Fruitflow
tomato-based bioactive by a major global food company into 2007, as
it continues to tweak the technology platform to make it suitable
for a spectrum of food products.
Drinking black tea could reduce stress hormone levels and help ease
the burden of heart disease, says the first randomized clinical
trial into the effects of the beverage on stress.
Extracts from tomatoes offer heart health benefits by reducing the
accumulation of platelets that lead eventually to blood clots,
heart attacks and strokes, say two complimentary studies from the
UK.
The strategy of demonstrating the potential of new technology with
an own-brand launch in order to garner interest from major industry
players seems to be paying off for Provexis, which has progressed
with global licensing discussions...
UK firm Provexis looks set to release a novel heart-healthy drink
next year after recent human trials on its tomato-based product
proved successful. CardioFlow is a concentrated tomato extract but
it contains no lycopene.
Dark chocolate could potentially reduce both cardiovascular and
thromboembolic disease, due to its high flavonoid-rich cocoa
content, suggests new research on chocolate consumption.
